JP2002542275A - 酸に対して不安定なプロトンポンプ阻害剤の固形医薬製剤 - Google Patents

酸に対して不安定なプロトンポンプ阻害剤の固形医薬製剤

Info

Publication number
JP2002542275A
JP2002542275A JP2000613405A JP2000613405A JP2002542275A JP 2002542275 A JP2002542275 A JP 2002542275A JP 2000613405 A JP2000613405 A JP 2000613405A JP 2000613405 A JP2000613405 A JP 2000613405A JP 2002542275 A JP2002542275 A JP 2002542275A
Authority
JP
Japan
Prior art keywords
omeprazole
acid
active substance
plot
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000613405A
Other languages
English (en)
Japanese (ja)
Inventor
ヘガー，ロベルト
シュロフ，ウォルフガング
リーガー，ヘンス
ボェルケル，ルーディガー
ブレイテンバッハ，ヨーグ
ツェイドラー，ユーゲン
リエポルド，ベアント
ベアンドル，グンター
ビンダー，ルドルフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of JP2002542275A publication Critical patent/JP2002542275A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000613405A 1999-04-23 2000-04-11 酸に対して不安定なプロトンポンプ阻害剤の固形医薬製剤 Withdrawn JP2002542275A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19918434.8 1999-04-23
DE19918434A DE19918434A1 (de) 1999-04-23 1999-04-23 Feste Pharmazeutische Formulierungen von säurelabilen Protonenpumpenblockern
PCT/EP2000/003232 WO2000064414A2 (de) 1999-04-23 2000-04-11 Feste pharmazeutische formulierungen von säurelabilen protonenpumpenblockern

Publications (1)

Publication Number Publication Date
JP2002542275A true JP2002542275A (ja) 2002-12-10

Family

ID=7905597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000613405A Withdrawn JP2002542275A (ja) 1999-04-23 2000-04-11 酸に対して不安定なプロトンポンプ阻害剤の固形医薬製剤

Country Status (6)

Country Link
EP (1) EP1173152A2 (pt)
JP (1) JP2002542275A (pt)
BR (1) BR0012735A (pt)
CA (1) CA2369951A1 (pt)
DE (1) DE19918434A1 (pt)
WO (1) WO2000064414A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502384A (ja) * 2017-11-10 2021-01-28 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー 改善された薬物製剤

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
MXPA03011933A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados.
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
CA2450957A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
CA2591983A1 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
CA2660383C (en) 2005-11-17 2013-12-24 Jon Pty Limited. Pharmacologically active disulfide compounds
AU2008304033B2 (en) * 2007-09-28 2014-05-01 Ctc Bio, Inc. Pharmaceutical composition containing esomeprazole
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
WO2013165468A1 (en) 2012-05-02 2013-11-07 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
US10064849B2 (en) * 2012-05-02 2018-09-04 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
DE102017008656B4 (de) 2017-09-15 2020-12-03 Glatt Maschinen- Und Apparatebau Ag Verfahren zur Regelung des Massen- oder Volumenstroms des Zerstäubergases einer Düse; Vorrichtung zur Regelung des Massen- oder Volumenstroms des Zerstäubergases einer Düse; Verwendung eines Verfahrens oder einer Vorrichtung zur Regelung des Massen- oder Volumenstroms des Zerstäubergases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19710213A1 (de) * 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
JP2001524131A (ja) * 1997-05-09 2001-11-27 セイジ、ファーマスーティカルズ、インク 安定な経口医薬品剤形

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502384A (ja) * 2017-11-10 2021-01-28 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー 改善された薬物製剤
JP7378393B2 (ja) 2017-11-10 2023-11-13 オースティンピーエックス リミテッド ライアビリティ カンパニー 改善された薬物製剤

Also Published As

Publication number Publication date
CA2369951A1 (en) 2000-11-02
EP1173152A2 (de) 2002-01-23
WO2000064414A2 (de) 2000-11-02
WO2000064414A3 (de) 2001-05-31
BR0012735A (pt) 2005-02-22
DE19918434A1 (de) 2000-10-26

Similar Documents

Publication Publication Date Title
DE69833157T2 (de) Stabile orale pharmazeutische Zusammensetzung enthaltend ein substituiertes Pyridylsulfinylbenzimidazol
JP4293750B2 (ja) ベンズイミダゾール誘導体を含む経口投与製剤及びその製造方法
EP0636364B1 (en) Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US20220211668A1 (en) Rapid disperse dosage form
US5626875A (en) Stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
EP1166777B1 (en) Taste masked pharmaceutical particles
EP1110544B1 (de) Verfahren zur Herstellung einer geschmacksmaskierten oralen Darreichungsform& x9;
RU2271805C2 (ru) Препарат, содержащий натеглинид
KR100421347B1 (ko) 약학 혼합 제제
US20020119196A1 (en) Texture masked particles containing an active ingredient
JP2002542275A (ja) 酸に対して不安定なプロトンポンプ阻害剤の固形医薬製剤
WO1996034628A1 (fr) Composition s'administrant par voie orale
CA2131569A1 (en) Formulation comprising antibacterial substance and antiulcer substance
EP0527637A1 (en) Spheroids containing dittiazem and a spheronizing agent
BRPI0608853A2 (pt) composições farmacêuticas gastrorresistentes contendo rifaximina, uso de microgránulos gastrorresistentes contendo rifaximina e processo para a fabricação das primeiras na forma de microgránulos gastrorresistentes
RU2259828C2 (ru) Способы стабилизации соединений на основе бензимидазола
US20050095285A1 (en) Pharmaceutical composition and a process for its preparation
CA2702356A1 (en) Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake
JP2000514051A (ja) ベンズイミダゾール誘導体を活性成分とする経口投与用の安定な薬剤形およびその製造方法
EP2198859A1 (en) Melt-coated pharmaceutical composition with fast release
KR100209201B1 (ko) 1,4-디히드로피리딘 유도체를 함유하는 고체 분산 정제 및 그의 제조방법
EP1018340B1 (en) Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them
KR20030059318A (ko) 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제
CA2779797A1 (en) Pharmaceutical solid dosage form
US8420115B2 (en) Oral preparations and process for production thereof

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20070703